Clinical trials: Pertussis Vaccines
dTap Vaccine
Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women
Pertussis (also known as whooping cough) is a highly contagious, vaccine-preventable respiratory tract disease, caused by the bacteria Bordetella pertussis.
- Trial name
- NCT05264662
- Testing
- Adacel (Tdap)
- Where
- South Africa
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- Farzanah Laher
Diphtheria, Hepatitis B
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.
The purpose of this study is to compare the reactogenicity \& safety of Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care, Tritanrix™-HepB/Hiberix™.
- Conditions
- Diphtheria, Hepatitis B, Whole Cell Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00317135
- Testing
- Tritanrix-HepB/Meningitec conjugate vaccine, Tritanrix/Hiberix vaccine
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster
Open-label, randomized, multi-centre study in which 400 subjects, divided into two groups, will receive Td5ap or Td1aP as a single injection.
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- Tdap Booster (NCT00870350)
- Testing
- Td5ap, Td1aP
- Where
- Sweden
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Diphtheria, Acellular Pertussis
Post Market Surveillance for Infanrix™
The purpose of this study was to investigate the following questions through post-marketing surveillance: Unknown/Unexpected adverse events and the serious adverse events.
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00908115
- Testing
- GSK Biologicals' Infanrix™
- Where
- South Korea
- Volunteers
- 1,258 people
- Sponsor
- GlaxoSmithKline
Heterologous Effects of Vaccines
Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly
Vaccines can have non-targeted or heterologous (also called non-specific) immunological effects on the immune system i.e. effects other than inducing an immune response against the disease targeted by the vaccine.
- Trial name
- NCT02765126
- Testing
- Seasonal influenza vaccine, Diphtheria-tetanus-acellular pertussis vaccine
- Where
- Australia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Clifford Craig Medical Research Trust
Apnea, Apnea Neonatal
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
A prospective, randomized open-label clinical trial will be conducted from July 2018 to October 2020. Approximately 300 preterm infants will be enrolled across three sites: Duke University Medical Center, the University of North…
- Conditions
- Apnea, Apnea Neonatal, Prematurity
- Trial name
- NCT03530124
- Testing
- PCV13, DTaP, HBV
- Where
- 4 sites in United States
- Volunteers
- 223 people
- Sponsor
- Duke University
Bordetella Pertussis, Whooping Cough
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
The resurgence of pertussis is associated with an evolutionary mechanism under the pressure of current acellular vaccines, with a possible impact on vaccine effectiveness and disease expression.
- Trial name
- PERT-SEVEREII (NCT05897879)
- Testing
- Nasopharyngeal swab, Blood samples
- Where
- 14 sites in France
- Volunteers
- 210 people
- Sponsor
- Institut Pasteur
Whooping Cough
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
The study contains three periods: screening, inpatient hospitalization and follow-up. And should be leaded as a randomized placebo-controlled study with in chain order enrolled volunteers and dose escalating.
- Trial name
- NCT03137927
- Testing
- Vaccine GamLPV
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Diphtheria, Tetanus
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
This study was designed to assess the lot comparability of DAPTACEL, as well as the safety and immunogenicity of DAPTACEL when co-administered with other recommended infant vaccines. Stage I Primary Objectives: 1.
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Polio
- Trial name
- NCT00662870
- Testing
- DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib
- Where
- 26 sites in United States
- Volunteers
- 1,941 people, healthy volunteers welcome
- Sponsor
- Sanofi
Vaccine Reaction
Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children
This study is to evaluate the immunogenicity and safety of DTaP or DT given in children aged 6 years.
- Trial name
- DTaP/DT (NCT05870618)
- Testing
- vaccinate with DTap, vaccinate with DT
- Where
- 2 sites in China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Vaccination
P3+ Intervention Phase
This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman…
- Trial name
- NCT02898688
- Testing
- Control Site, Intervention Site, Patient-level Control Group
- Where
- 23 sites in United States
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Emory University
Diphtheria, Tetanus
A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
This is a randomized, blinded, controlled phase II and III clinical trial evaluating the immunogenicity and safety of adsorbed cell-free DPT vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT06708286
- Testing
- Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp
- Where
- China
- Volunteers
- 1,820 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Diphtheria, Tetanus
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
To assess the safety and reactogenicity of the DTPa-IPV/Hib vaccine as primary and booster vaccination. The DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis, Acellular Pertussis
- Trial name
- NCT00325156
- Testing
- GSK Biologicals' combined DTPa-IPV/Hib vaccine
- Where
- Singapore
- Volunteers
- 2,590 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of a new live attenuated vaccine against whooping-cough. It is a phase1, single centre, dose-escalating, placebo-controlled study on a genetically modified B.
- Trial name
- NCT01188512
- Testing
- BPZE1
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hepatitis B, Polio
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
The purpose of the study is to provide immunogenicity and safety data of the investigational hexavalent vaccine when it is given concomitantly (the same day at separate injection sites) with Prevnar, according to the 2-4-6 month…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00401531
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pertussis
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
OBJECTIVES: I. Compare the efficacy of 2 acellular pertussis vaccines vs. whole-cell pertussis vaccine vs. placebo in infants living in Italy. II. Compare the relative protection of each of the acellular vaccines vs.
- Trial name
- NCT00004800
- Testing
- diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis, diphtheria-tetanus vaccine
- Volunteers
- 13,250 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tetanus, Hepatitis B
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.
- Conditions
- Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Poliomyelitis
- Trial name
- NCT01090453
- Testing
- GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™
- Where
- 34 sites in Canada, France and 1 more
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.
To evaluate the immunogenicity, persistence of antibodies and reactogenicity of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX), when administered to subjects 18-20 months old, compared with not giving a booster DTP vaccine…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00544271
- Testing
- INFANRIX, BOOSTRIX, HAVRIX
- Where
- Australia
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Haemophilus Influenzae Type b
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers
This study aims to evaluate the safety and reactogenicity of a booster dose of Infanrix-IPV+Hib™ when administered to healthy Vietnamese toddlers at 12 to 24 months of age who were vaccinated previously against diphtheria…
- Conditions
- Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus, Poliomyelitis
- Trial name
- NCT01577732
- Testing
- Infanrix-IPV+Hib™
- Where
- Vietnam
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis, Diphtheria
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00287092
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib
- Where
- 14 sites in Finland, Sweden
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company